Rho kinase Blockade Ameliorates DSS-Induced Ulcerative Colitis in Mice Through Dual Inhibition of the NF-κB and IL-6/STAT3 Pathways
- 8 January 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Inflammation
- Vol. 43 (3), 857-867
- https://doi.org/10.1007/s10753-019-01171-2
Abstract
Inflammatory bowel disease (IBD) has received much attention due to its increasing worldwide incidence and potential increased risk of colorectal cancer. The protective function of a Rho-associated protein kinase inhibitor (Y-27632) against 2,4,6-trinitrobenzene sulfonic acid (TNBS) induced mouse colitis has been proven in previous studies, but the concrete therapeutic mechanism of Y-27632 is still not completely illuminated. This current research is intended for further investigation of the effect and mechanism of Y-27632 in a mouse model of acute experimental ulcerative colitis induced by dextran sulfate sodium (DSS). A total of 24 male BALB/c mice were randomly separated into the following three groups (n = 8 per group) and injected intraperitoneally with the corresponding reagents for 7 days: control group (PBS), DSS group (PBS), and Y-27632 group (PBS and Y-27632; 10 mg/kg). Our data indicated that Y-27632 could significantly improve the severity of colitis, as evidenced by the disease activity index (DAI) scores, histological damage, and colon length. Additionally, Y-27632 treatment significantly decreased CD68 and proinflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-17F (IL-17F), and interleukin-6 (IL-6). Furthermore, Y-27632 potently and pleiotropically suppressed nuclear factor-κB (NF-κB) and signal transduction and transcriptional activator 3 (STAT3) activation as well as the activity of prosurvival genes that are dependent on these transcription factors. In summary, the study demonstrates that Y-27632 exerts ameliorative effects on colonic inflammation mediated through dual inhibition of the NF-κB and IL-6/STAT3 pathways and thus is likely to function as a prospective novel treatment for human ulcerative colitis (UC).Keywords
Funding Information
- National Natural Science Foundation of China (81774093, 81573784)
This publication has 33 references indexed in Scilit:
- Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature reviewWorld Journal of Gastroenterology, 2019
- The anti-inflammatory activity of peptides from simulated gastrointestinal digestion of preserved egg white in DSS-induced mouse colitisFood & Function, 2018
- Periplaneta americana Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Rats by Keap1/Nrf-2 Activation, Intestinal Barrier Function, and Gut Microbiota RegulationFrontiers in Pharmacology, 2018
- Helicobacter pylori Colonization Protects Against Chronic Experimental Colitis by Regulating Th17/Treg BalanceInflammatory Bowel Diseases, 2018
- Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel DiseaseMediators of Inflammation, 2017
- Antioxidant therapy for treatment of inflammatory bowel disease: Does it work?Redox Biology, 2015
- Cytokines in inflammatory bowel diseaseNature Reviews Immunology, 2014
- Long-term intake of dietary fat and risk of ulcerative colitis and Crohn's diseaseGut, 2013
- A novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in miceJournal of Crohn's and Colitis, 2012
- Defects in mucosal immunity leading to ulcerative colitisImmunological Reviews, 2005